The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Open accessAbstract
BACKGROUND: Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM. METHODS: We conducted a population-based, retrospective cohort study of 12,500 women diagnosed with incident, invasive breast cancer from January 1, 1999 through December 31, 2007, at eight integrated Cancer Research Network health systems. Using administrative procedure and pharmacy codes, we identified anthracycline, trastuzumab, and other chemotherapy use. We identified incident HF/CM following chemotherapy initiation and assessed risk of HF/CM with time-varying chemotherapy exposures vs no chemotherapy. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with adjustment for age at diagnosis, stage, Cancer Research Network site, year of diagnosis, radiation therapy, and comorbidities. RESULTS: Among 12 500 women (mean age = 60 years, range = 22-99 years), 29.6% received anthracycline alone, 0.9% received trastuzumab alone, 3.5% received anthracycline plus trastuzumab, 19.5% received other chemotherapy, and 46.5% received no chemotherapy. Anthracycline and trastuzumab recipients were younger, with fewer comorbidities than recipients of other chemotherapy or none. Compared with no chemotherapy, the risk of HF/CM was higher in patients treated with anthracycline alone (adjusted HR = 1.40, 95% CI = 1.11 to 1.76), although the increased risk was similar to other chemotherapy (adjusted HR = 1.49, 95% CI = 1.25 to 1.77); the risk was highly increased in patients treated with trastuzumab alone (adjusted HR = 4.12, 95% CI = 2.30 to 7.42) or anthracycline plus trastuzumab (adjusted HR = 7.19, 95% CI = 5.00 to 10.35). CONCLUSIONS: Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Owens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Cited by
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
A population-based study of cardiovascular disease mortality risk in US cancer patients
Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 923
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21341 · Cited by 723
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563
Armenian, S. H., Xu, L., Ky, B., Sun, C., Farol, L. T., Pal, S. K., Douglas, P. S., Bhatia, S., & Chao, C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0409 · Cited by 559
Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
Strongman, H., Gadd, S., Matthews, A., Mansfield, K. E., Stanway, S., Lyon, A. R., dos-Santos-Silva, I., Smeeth, L., & Bhaskaran, K. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31674-5 · Cited by 509
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P. M., Krol, A. D. G., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4444 · Cited by 464
Pituskin, E., Mackey, J. R., Koshman, S., Jassal, D., Pitz, M., Haykowsky, M. J., Pagano, J. J., Chow, K., Thompson, R. B., Vos, L. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.7830 · Cited by 408
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Kim, S. J., Kim, H. S., & Seo, Y. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5381692 · Cited by 406
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002661 · Cited by 334
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
Ezaz, G., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 276
Sex differences in cardiovascular disease – Impact on care and outcomes
Humphries, K. H., Izadnegahdar, M., Sedlak, T., Saw, J., Johnston, N., Schenck-Gustafsson, K., Shah, R. U., Regitz-Zagrosek, V., Grewal, J., Vaccarino, V., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.04.001 · Cited by 273
Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Hahn, V. S., Lenihan, D. J., & Ky, B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000665 · Cited by 264
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Denlinger, C. S., Sanft, T., Baker, K. S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., Goldman, M., Hudson, M., Khakpour, N., King, A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0078 · Cited by 199
Cardiovascular disease in cancer survivors
Okwuosa, T. M., Anzevino, S., & Rao, R. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134417 · Cited by 97
Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires
Conant, G., Ahadian, S., Zhao, Y., & Radisic, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12048-5 · Cited by 25
Metadata
- Authors
- Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., Habel, L. A., Yood, M. U., Mccarty, C., Magid, D. J., Wagner, E. H., & Pharmacovigilance Study Team
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-30
- Volume
- 104
- Issue
- 17
- Pages
- 1293-1305
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2105436256
- Cited by
- 566
- References
- 36
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.